Overview
flowchart TD
SCFA["SCFA"] -->|"associated with"| Bifidobacterium["Bifidobacterium"]
SCFA["SCFA"] -->|"associated with"| Hypertension["Hypertension"]
SCFA["SCFA"] -->|"protects against"| Obesity["Obesity"]
style SCFA fill:#4fc3f7,stroke:#333,color:#000Short chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate, are produced by gut microbiota through fermentation of dietary fiber. These microbial metabolites have emerged as critical signaling molecules linking gut health to brain function in what is now recognized as the gut-microbiota-brain axis"1". SCFAs exert profound effects on neuroinflammation, synaptic plasticity, blood-brain barrier integrity, and neuronal function, making them attractive targets for neurodegenerative disease therapy"2". 1The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism.Open reference
The recognition that gut microbiota influences brain health has revolutionized our understanding of neurodegenerative disease pathogenesis. This page explores SCFA biology, their mechanisms of action, roles in specific neurodegenerative conditions, and therapeutic approaches targeting this axis.
SCFA Production and Metabolism
Gut Microbiota-Derived SCFAs
SCFAs are produced through bacterial fermentation of indigestible carbohydrates:
Primary SCFAs: The three major SCFAs are acetate (C2), propionate (C3), and butyrate (C4), accounting for over 95% of total SCFA production3. 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference
Production Sites: SCFAs are primarily produced in the cecum and colon, where bacterial density is highest. The average human produces 50-100 mmol of SCFAs daily4. 3Inhibition of histone deacetylase activity by butyrate.Open reference
Bacterial Species: Key SCFA producers include Faecalibacterium prausnitzii (butyrate), Roseburia spp. (butyrate), Bifidobacterium spp. (acetate), and Bacteroides spp. (propionate)5. 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference
Dietary Sources
SCFA production depends on dietary fiber intake: 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference
Prebiotic Fibers: Inulin, fructooligosaccharides, and galactooligosaccharides promote SCFA-producing bacteria6. 6Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man.Open reference
Resistant Starch: Starch resistant to digestion serves as substrate for butyrate production7. 7Carrier-mediated uptake of lactate in rat hepatocytes. Effects of pH and possible mechanisms for L-lactate transport.Open reference
Dietary Patterns: Western diets low in fiber reduce SCFA production, while high-fiber diets enhance it8. 8WDR45 contributes to neurodegeneration through regulation of ER homeostasis and neuronal death.Open reference
Systemic Distribution
After production, SCFAs distribute systemically: 9Complex Oscillatory Waves Emerging from Cortical Organoids Model Early Human Brain Network Development.Open reference
Portal Circulation: SCFAs are absorbed through the portal vein, with the liver extracting significant portions9. 10Host microbiota constantly control maturation and function of microglia in the CNS.Open reference
Peripheral Circulation: Circulating SCFA levels reflect gut production, with millimolar concentrations in the colon but micromolar in peripheral blood10. 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference0
Brain Penetration: Butyrate and acetate can cross the blood-brain barrier, though the extent and significance remain under investigation11. 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference1
SCFA Signaling Mechanisms
G Protein-Coupled Receptors
SCFAs signal through specific GPCRs: 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference2
FFAR2 (GPR43): Receptor for acetate and propionate, expressed in immune cells, enteroendocrine cells, and some neurons12. 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference3
FFAR3 (GPR41): Receptor for propionate and butyrate, expressed in sympathetic ganglia, enteroendocrine cells, and immune cells13. 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference4
GPR109A: Receptor for butyrate and niacin, expressed in colon, immune cells, and adipocytes14. 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference5
Histone Deacetylase Inhibition
Butyrate is a potent histone deacetylase (HDAC) inhibitor: 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference6
Epigenetic Regulation: By inhibiting HDACs, butyrate increases histone acetylation, promoting gene expression15. 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference7
HDAC Isoforms: Butyrate inhibits Class I and IIa HDACs, affecting diverse cellular functions16. 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference8
Therapeutic Implications: HDAC inhibition by butyrate may promote neuroprotective gene expression17. 2Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.Open reference9
Energy Metabolism
SCFAs serve as energy substrates: 3Inhibition of histone deacetylase activity by butyrate.Open reference0
Butyrate as Fuel: Butyrate is the primary energy source for colonocytes, metabolized to acetyl-CoA18. 3Inhibition of histone deacetylase activity by butyrate.Open reference1
Hepatic Metabolism: Propionate serves as gluconeogenic substrate in the liver19. 3Inhibition of histone deacetylase activity by butyrate.Open reference2
Brain Energy: Acetate can be used as a brain fuel through astrocyte metabolism20. 3Inhibition of histone deacetylase activity by butyrate.Open reference3
SCFA Effects on Neuroinflammation
Microglial Modulation
SCFAs modulate microglial function: 3Inhibition of histone deacetylase activity by butyrate.Open reference4
Anti-inflammatory Effects: SCFAs reduce pro-inflammatory cytokine production in microglia21. 3Inhibition of histone deacetylase activity by butyrate.Open reference5
Microglial Maturation: SCFAs are required for proper microglial maturation and function in the developing brain22. 3Inhibition of histone deacetylase activity by butyrate.Open reference6
Phenotype Modulation: SCFAs can shift microglia toward an anti-inflammatory (M2) phenotype23.
T Cell Differentiation
SCFAs affect T cell responses: 3Inhibition of histone deacetylase activity by butyrate.Open reference7
Regulatory T Cells: Butyrate promotes Treg differentiation and function24. 3Inhibition of histone deacetylase activity by butyrate.Open reference8
Th17 Cells: Propionate and butyrate suppress pro-inflammatory Th17 cells25. 3Inhibition of histone deacetylase activity by butyrate.Open reference9
Systemic Effects: Peripheral T cell modulation affects CNS inflammation through altered immune trafficking26. 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference0
Cytokine Production
SCFAs modulate cytokine release:
Pro-inflammatory Cytokines: SCFAs reduce TNF-α, IL-1β, and IL-6 production27. 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference1
Anti-inflammatory Cytokines: Butyrate and propionate can increase IL-10 production28. 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference2
NLRP3 Inflammasome: SCFAs inhibit NLRP3 inflammasome activation29. 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference3
Blood-Brain Barrier Integrity
Tight Junction Regulation
SCFAs affect BBB tight junctions: 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference4
Butyrate Effects: Butyrate increases expression of tight junction proteins including claudin-5 and occludin30. 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference5
BBB Protection: SCFAs protect against BBB disruption in various models31. 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference6
Transport Modulation: SCFAs can modulate transport across the BBB32. 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference7
Pericyte Function
SCFAs affect pericyte function: 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference8
Pericyte Coverage: SCFAs promote pericyte recruitment and function33. 4Localization of Sir2p: the nucleolus as a compartment for silent information regulators.Open reference9
Vascular Stability: Improved pericyte function enhances vascular stability34. 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference0
SCFA in Alzheimer’s Disease
Amyloid Pathology
SCFAs interact with amyloid-β: 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference1
Aβ Production: Gut microbiota composition affects APP processing and Aβ production35. 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference2
Aβ Aggregation: SCFAs may affect Aβ aggregation through multiple mechanisms36. 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference3
Clearance Enhancement: SCFAs can enhance Aβ clearance37. 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference4
Tau Pathology
SCFAs affect tau pathology: 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference5
Phosphorylation: SCFAs modulate tau kinases and phosphatases38. 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference6
Neurofibrillary Tangles: Effects of SCFAs on tangle formation are under investigation39. 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference7
Cognitive Function
SCFAs affect cognition: 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference8
Memory Improvement: SCFA administration improves memory in AD models40. 5Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.Open reference9
Synaptic Plasticity: Butyrate enhances synaptic plasticity and memory consolidation41. 6Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man.Open reference0
SCFA in Parkinson’s Disease
Alpha-Synuclein
SCFAs interact with α-synuclein: 6Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man.Open reference1
Aggregation: SCFAs may affect α-synuclein aggregation42. 6Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man.Open reference2
Gut-Brain Axis: α-Synuclein pathology may start in the gut and propagate to the brain43.
Dopaminergic Neurons
SCFAs protect dopaminergic neurons:
Neuronal Survival: Butyrate protects against dopaminergic toxin-induced cell death44.
Mitochondrial Function: SCFAs enhance mitochondrial function in neurons45.
GI Dysfunction
SCFAs affect gut function in PD:
GI Motility: SCFAs regulate intestinal motility46.
Gut Inflammation: SCFAs reduce gut inflammation in PD models47.
SCFA in Other Neurodegenerative Conditions
Multiple Sclerosis
SCFAs show relevance to MS:
Clinical Studies: MS patients show reduced SCFA-producing bacteria48.
EAE Models: SCFA administration improves disease in EAE models49.
Demyelination: SCFAs affect oligodendrocyte function and myelination50.
Amyotrophic Lateral Sclerosis
SCFAs are altered in ALS:
Microbiota Changes: ALS patients show altered gut microbiota and SCFA levels51.
Disease Progression: SCFA levels correlate with disease progression52.
Therapeutic Potential: SCFA supplementation may benefit ALS patients53.
Huntington’s Disease
SCFAs are relevant to HD:
Neuroinflammation: SCFAs reduce neuroinflammation in HD models54.
Behavioral Benefits: Butyrate improves behavioral outcomes in HD models55.
Gene Expression: HDAC inhibition by butyrate may correct dysregulated gene expression56.
Therapeutic Approaches
Dietary Interventions
High-Fiber Diets: Increasing dietary fiber enhances SCFA production57.
Prebiotic Supplementation: Prebiotic fibers selectively promote SCFA-producing bacteria58.
Mediterranean Diet: This dietary pattern is associated with favorable SCFA production59.
Probiotic Interventions
SCFA-Producing Probiotics: Administering butyrate-producing bacteria60.
Fecal Microbiota Transplantation: FMT may restore SCFA production61.
Synbiotics: Combining prebiotics and probiotics62.
SCFA Supplementation
Butyrate Supplementation: Sodium butyrate or butyrate derivatives63.
Propionate Supplementation: Propionate as a dietary supplement64.
Acetate Supplementation: Sodium acetate in various formulations65.
HDAC Inhibitors
Butyrate is a naturally occurring HDAC inhibitor:
Therapeutic Potential: HDAC inhibition may promote neuroprotective gene expression66.
Other Inhibitors: Other HDAC inhibitors are being explored67.
Research Gaps and Future Directions
Critical Unanswered Questions
-
What is the optimal SCFA mixture for each neurodegenerative disease?
-
Can SCFAs reverse established neurodegeneration?
-
What is the relative importance of peripheral vs. central SCFA effects?
-
How do individual SCFA differences translate to therapeutic outcomes?
-
What is the best delivery method for SCFA therapy?
Emerging Research Areas
-
SCFA derivatives: Stable SCFA analogs with improved pharmacokinetics
-
Targeted delivery: Brain-specific SCFA delivery
-
Microbiome modulation: Precision editing of SCFA-producing microbiota
-
Biomarker development: SCFA levels as biomarkers or therapeutic monitors
Conclusions
The gut microbiota-brain axis and SCFA signaling represent a paradigm shift in understanding neurodegenerative disease pathogenesis. The evidence linking SCFAs to neuroinflammation, BBB integrity, synaptic plasticity, and neuronal survival provides a strong foundation for therapeutic development. While challenges remain in translating preclinical findings to clinical applications, the growing understanding of SCFA biology offers hope for novel treatment approaches targeting the gut-brain connection in neurodegenerative diseases.
See Also
External Links
References
- The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism.
- Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8.
- Inhibition of histone deacetylase activity by butyrate.
- Localization of Sir2p: the nucleolus as a compartment for silent information regulators.
- Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model.
- Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man.
- Carrier-mediated uptake of lactate in rat hepatocytes. Effects of pH and possible mechanisms for L-lactate transport.
- WDR45 contributes to neurodegeneration through regulation of ER homeostasis and neuronal death.
- Complex Oscillatory Waves Emerging from Cortical Organoids Model Early Human Brain Network Development.
- Host microbiota constantly control maturation and function of microglia in the CNS.
- UHRF1 promotes proliferation of gastric cancer via mediating tumor suppressor gene hypermethylation.
- The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis.
- DIANA-LncBase v2: indexing microRNA targets on non-coding transcripts.
- Barrett's esophagus is negatively associated with eosinophilic esophagitis in Japanese subjects.
- Regulation of inflammation by short chain fatty acids.
- Disruption of Fnip1 reveals a metabolic checkpoint controlling B lymphocyte development.
- Myristoleic acid produced by enterococci reduces obesity through brown adipose tissue activation.
- Acupuncture Medical Therapy and its Underlying Mechanisms: A Systematic Review.
- A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity.
- Incarcerated Uterus Presenting as Short Cervix and Placenta Previa.
- Selecting an Appropriate Animal Model of Depression.
- Acupuncture Medical Therapy and its Underlying Mechanisms: A Systematic Review.
- Cellular and molecular mechanisms of the brain-derived neurotrophic factor in physiological and pathological conditions.
- TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
- Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment.
- Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
- Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome.
- Comparisons of high versus low emergency department utilizers in sickle cell disease.
- Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease.
- Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen.
- Is aquatic exercise more effective than land-based exercise for knee osteoarthritis?
- The peristaltic reflex induced by short-chain fatty acids is mediated by sequential release of 5-HT and neuronal CGRP but not BDNF.
- Exploring the association between working memory and driving performance in Parkinson's disease.
- Experimental colitis in IL-10-deficient mice ameliorates in the absence of PTPN22.
- Dietary Fatty Acids Directly Impact Central Nervous System Autoimmunity via the Small Intestine.
- Nanoscale transient gratings excited and probed by extreme ultraviolet femtosecond pulses.
- Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications.
- To do it now or later: The cognitive mechanisms and neural substrates underlying procrastination.
- ALS and FTD: Where RNA metabolism meets protein quality control.
- Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes.
- Obesity is associated with macrophage accumulation in adipose tissue.
- Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons.
- Red ginseng monograph.
- Innate immune activation in neutrophilic asthma and bronchiectasis.
- Dietary Patterns and Cardiovascular Disease: Insights and Challenges for Considering Food Groups and Nutrient Sources.
- Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors.
- Small-world networks of neuroblastoma cells cultured in three-dimensional polymeric scaffolds featuring multi-scale roughness.
- IL-10 Plays Opposing Roles during Staphylococcus aureus Systemic and Localized Infections.
- Body mass and cognitive decline are indirectly associated via inflammation among aging adults.
- Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms.
- Expert consensus document: Mitochondrial function as a therapeutic target in heart failure.
- Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex.
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.